

1 **Effect of Adjunctive Intraoral Balance Appliance in the Usual Care of**
2 **Patients with Chronic Temporomandibular Joint Disorders using**
3 **Korean Medicine: Study Protocol for a Randomized Controlled Trial**

4 **Woo-Chul Shin¹, Se yun Kim¹, Whisung Cho², Jaehyun Park^{2,3}, Hyungsuk Kim^{1,2}, Won-**
5 **Seok Chung^{1,2}, Mi-Yeon Song^{1,2}, Jae-Heung Cho^{1,2,*}**

6

7 ¹Department of Korean Medicine Rehabilitation, College of Korean Medicine, Kyung Hee University
8 Korean Medicine Hospital, Seoul, Republic of Korea

9 ²Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea

10 ³Miall Hospital of Korean Medicine

11

12 ***Correspondence:**

13 Jae-Heung Cho, Department of Clinical Korean Medicine Graduate School, Kyung Hee
14 University, 23 Kyungheedaero, Dongdaemun-gu, Seoul, Republic of Korea

15 vetkong95@hanmail.net

16

17

18

19

20

21 **ABSTRACT**

22 **Introduction**

23 Temporomandibular disorders (TMD) are a group of conditions that affect the temporomandibular joint,
24 masticatory muscles, and associated structures, often leading to pain, dysfunction, and a significant
25 impact on quality of life. Epidemiological studies have estimated that up to 75% of the population in
26 the United States exhibit at least one sign of TMD. Although conservative treatments such as
27 acupuncture and occlusal splints have been recommended, evidence for their effectiveness remains
28 inconclusive, and the combined effects of these interventions are not well understood.

29 This study aims to compare the efficacy of an intraoral balance appliance (IBA) combined with
30 standard Korean medicine care versus Korean medicine care alone in patients with chronic, painful
31 TMD with myalgia.

32 **Materials and Methods**

33 A single-center, two-arm, parallel, evaluator-blinded, randomized controlled trial (RCT) with a 1:1
34 allocation ratio will be designed to test the interventions. Seventy-six TMD patients with myalgia will
35 be recruited and randomized. The Interventions will include manual acupuncture and physical therapy
36 in both groups, with the addition of IBA in the treatment group.

37 **Discussion**

38 The outcomes will be measured using various scales such as the numeric rating scale for pain and
39 bothersomeness, jaw functional limitation scale, and quality of life indicators.

40 **Conclusion**

41 The trial is expected to provide evidence of the efficacy of combining the usual Korean medicine care
42 and IBA in managing chronic TMD myalgia. Despite certain limitations such as the short intervention
43 period and lack of standardized splint therapy, this RCT will contribute valuable data to guide the future

44 treatment of TMD with myalgia.

45 **Trial registration:** Clinical Research information Service (CRiS) ID: KCT0008906. Registered on
46 October 30, 2023

47 **Keywords:** temporomandibular disorder, occlusal splint, Korean medicine, Complementary
48 therapies

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63 **Introduction**

64 The temporomandibular joint (TMJ) is the only bilateral synovial joint in the human body [1]. This
65 allows opening and closing of the mouth for mastication, which is essential for the life-sustaining
66 functions of the body. Temporomandibular disorders (TMD) are a subgroup of craniofacial pain
67 problems that involve the TMJ, masticatory muscles, and associated head and neck musculoskeletal
68 structures [2]. Temporomandibular disorders can lead to a cluster of symptoms, including jaw pain,
69 facial pain, headache, and associated psychological and psychosocial problems. Given the varied
70 subgroups of symptoms and signs present in TMD, the etiological factors are recognized as
71 multifactorial, encompassing biological, behavioral, environmental, social, emotional, and cognitive
72 influences, either independently or in combination, contributing to the disorder. According to the
73 diagnostic criteria for TMD (DC/TMD), TMD can be classified as either intra- or extra-articular [3].
74 Extra-articular conditions, which usually involve musculature problems surrounding the TMJ, are the
75 most common causes of TMD, accounting for at least 50% of TMD cases [4]. Additionally, among the
76 various signs and symptoms of TMD, pain-related TMD is more common and significantly affects an
77 individual's daily activities. Epidemiological studies have shown that 40–75% of the population
78 exhibits at least one of the signs of TMD [2]. Additionally, the OPPERA project (Orofacial Pain:
79 Prospective Evaluation and Risk Assessment) estimated the annual incidence of TMD to be
80 approximately 4% in the US population [5], with a 20.4% prevalence of chronic pain, indicating that
81 TMD represents a major public health burden.

82 One suggested initial approach for TMD, particularly of myogenous origin, is conservative
83 management because of its multifaceted causes and unknown precise pathogenesis. Conservative
84 treatment modalities include counseling, medication, exercise, occlusal splints, and acupuncture [4].
85 Among the treatment modalities, acupuncture has garnered widespread adoption, particularly in East
86 Asian countries, owing to its relatively few adverse effects and notable analgesic efficacy. Multiple
87 controlled trials have reported the efficacy of acupuncture on pain conditions, such as myofascial pain,

88 tension headache, and fibromyalgia. [6] Similar to myofascial pain conditions, TMD with myalgia is
89 often associated with tender points in related masticatory muscles. Systematic reviews have shown that
90 acupuncture reduces the signs and symptoms of myofascial TMD pain; however, the quality of the
91 included studies was low [7, 8]. Another conservative treatment option is occlusal splints. One of the
92 main pathologies of TMD is mechanical displacement, usually within the disc-condyle relationship.
93 Various splints are used to restore static and dynamic occlusions, relax the relevant musculature, and
94 reduce physiological stress in joint structures [9]. Several systematic reviews have indicated the benefits
95 of occlusal splints in treating TMD [10]. Moreover, a recent network meta-analysis demonstrated that
96 occlusal splints are one of the most effective treatment modalities for TMD, yielding significant benefits
97 in both short and intermediate terms [11].

98 Despite the reported advantages of various treatments for TMD, a definitive consensus regarding the
99 most efficacious treatment is still lacking as insufficient conclusive evidence is unavailable.
100 Consequently, a multidisciplinary approach is usually recommended in clinical practice [12]; however,
101 many interventions have not yet been rigorously tested.

102 We aim to compare the efficacy of incorporating an intraoral balance appliance (IBA) alongside the
103 usual care for patients with chronic painful TMD using Korean medicine and evaluate its effectiveness
104 on patient's functional, clinical outcomes (pain, bothersomeness, vertical range of motion (ROM),
105 graded chronic pain scale (GCPS), jaw functional limitation scale (JFLS), patient health questionnaire-9
106 (PHQ-9), quality of life (EQ-5D-5L), and patient global impression of change (PGIC)), and adverse
107 events (AEs).

108

109 **Materials and methods**

110 **Trial design**

111 This is a single-center, two-arm, parallel, evaluator-blind randomized controlled trial with a 1:1

112 allocation ratio. The study will be performed at Kyung Hee University Medical Center, Korean
113 Medicine Hospital, Korea. The reporting of the protocol will adhere to the Standard Protocol Items:
114 Recommendations for Interventional Trials (SPIRIT) (S1 table) [13]. The trial follows the Consolidated
115 Standards of Reporting Trials (CONSORT) reporting guidelines and the Standards for Reporting
116 Interventions in Clinical Trials of Acupuncture (STRICTA) recommendations (S2 table) [14].

117

118 **Ethics approval**

119 Ethical approval was obtained from the Institutional Review Board of Kyung Hee University Korean
120 Medicine Hospital Institutional Review Board (IRB number: KOMCIRB 2023-06-001). We will obtain
121 informed consent from each eligible participant, and collect data anonymously to maintain privacy. This
122 study will be conducted in full conformity with the 1964 Declaration of Helsinki and all subsequent
123 revisions and in accordance with the Good Clinical Practice Guidelines. The protocol will be registered
124 at the Clinical Research information Service (CRiS), Republic of Korea, on October 30, 2023 (CRiS
125 number KCT0008906) before enrollment of the first participant.

126

127 **Sample size calculation**

128 This study is a prospective study that will compare the effects of different IBA. Referring to a previous
129 study that compared treatments for painful masticatory muscles [15], an appropriately powered full-
130 scale sample size will be estimated using the mean difference of the numeric rating scale (NRS) for
131 pain owing to TMD with myalgia between groups at the primary endpoint. The effect size d according
132 to the change in the reference study is 0.74, and with 80% power, 0.05 alpha, and a two-sided test, the
133 number of samples required for each group will be 30. The total sample size required, when considering
134 a dropout rate of 20%, will be 76 participants, with 38 participants in each group. The sample size will
135 be determined using G*Power 3.1.7 software.

136

137 **Methods of recruitment**

138 Recruitment will be accomplished by issuing press releases about the study, advertisements in free
139 newspapers, and displaying posters within and outside Kyung Hee University Medical Center Korean
140 Medicine Hospital in Seoul, Korea. The estimated recruitment period is 12 months.

141

142 **Eligibility criteria**

143 The inclusion criteria will be as follows:

144 1) Participants aged between 19–70 years on the date of signing the informed consent form.

145 2) Participants with unilateral or bilateral TMJ pain.

146 3) Participants with a NRS of ≥ 4 at the site of TMJ pain (based on the side with more pain for
147 participants with bilateral pain).

148 4) Participants with persistent or intermittent TMJ pain for ≥ 3 months.

149 5) Participants with a diagnosis of TMD with myalgia according to the DC/TMD diagnostic criteria.

150 6) Participants who voluntarily agree to participate in the study and sign a written informed consent
151 form prior to any study-related procedures.

152

153 The exclusion criteria will be as follows:

154 1) Current pain episode caused or exacerbated by traumatic injuries such as motor vehicle accidents.

155 2) Individuals who do not meet the diagnosis of TMD with myalgia according to the DC/TMD
156 diagnostic criteria.

- 157 3) Undergone surgery related to TMJ.
- 158 4) Concomitant medical conditions that may interfere with the efficacy of treatment or interpretation
159 of results (e.g., rheumatoid arthritis, tumor, stroke, and myocardial infarction)
- 160 5) Participants currently taking steroidal agents, immunosuppressants, psychiatric medications, and
161 other medications that may affect the results of the trial.
- 162 6) Participants who have taken medications that may affect pain, such as non-steroidal anti-
163 inflammatory drugs within the past week, or have applied orthodontic appliances in the past two
164 weeks, regardless of the condition.
- 165 7) Participants who are pregnant, planning to become pregnant, or breastfeeding women.
- 166 8) Participated in another clinical trial within one month before the date of enrollment, or plans to
167 participate in another clinical trial during the study participation and follow-up period.
- 168 9) Other reasons deemed by the investigator that may present difficulties to participate in the trial.

169

170 Participants in the trial will voluntarily sign the written informed consent forms in accordance with the
171 Declaration of Helsinki and Guidelines for Good Clinical Practice. The consent form will be collected
172 by the participating Korean medicine doctors (KMDs) or a participating clinical research coordinator.

173

174 **Randomization and allocation strategy**

175 Randomization will be conducted using computer-generated random numbers. A statistician who is not
176 involved in the intervention process will generate computer-generated random numbers. Blocked
177 randomization will be used to ensure a balance between the two groups, with the block size kept
178 confidential from those involved in patient enrollment or intervention assignment. The randomized

179 numbers will be assigned to screen the participants in the order of recruitment. The designated
180 investigator will provide the intervention arm to the practitioners. The generated random numbers will
181 be sealed in an envelope and stored by an investigator who will not engage with the participants.

182

183 **Dropout and withdrawal**

184 If any participants voluntarily withdraw their consent at any point during the study or if an adverse
185 event (AE) that is considered harmful to the participants is observed, the investigator will temporarily
186 or permanently discontinue the study for the respective participants. Detailed reasons for any interrupted
187 study trials will be recorded by the investigator. If early withdrawal owing to an AE occurs, appropriate
188 treatment will be provided and the investigator will continue to monitor the participant until the AE
189 resolves. In case of consent withdrawal, no further follow-up will be conducted. The investigator may
190 also terminate the study if the participant receives a procedure, medication, or other treatments that
191 could affect the study without permission. Study participants who withdraw before treatment initiation
192 will be considered screening failures.

193 The investigators will make every effort to obtain information about the patients who drop out and
194 record the reason for discontinuation in the electronic case report forms (eCRF).

195

196 **Blinding**

197 This will be an open-label study with participants and practitioners being aware of treatment allocation.
198 Only the outcome evaluator will be blinded to the intervention arm. Therefore, unblinding will be
199 unnecessary in any circumstances.

200

201 **Participants' timeline**

202 The duration of the study will be four weeks. A timeline of this study is shown in Fig 1.

203 **Fig 1. SPIRIT schedule of enrollment, interventions, and assessments.**

204

205 **Interventions**

206 Participants will be randomized into treatment and control groups. Both groups will receive the usual
207 care of Korean medicine consisting of manual acupuncture and physical therapy. The treatment group
208 will receive additional IBA (JinBiotech®, Cheonan, Korea). Owing to the inherent nature of splint
209 therapy, creating a placebo group is fundamentally impractical; therefore, it will not be included in this
210 study. Acupuncture and physical therapy will be administered twice a week for three weeks, with a total
211 of six treatment sessions for both the treatment and control groups.

212 Manual acupuncture will be performed at four essential acupuncture points: Xiaguan (ST7), Jiache
213 (ST6), Ermen (TE21), and Yifeng (TE17). Additional ‘ashi points,’ which are tender points in
214 associated musculature, will be determined by the participating KMDs. Manual acupuncture will be
215 administered using disposable sterile stainless-steel needles (40 × 0.25 mm; Dong-bang Medical,
216 Seongnam, Korea) after skin sterilization with the participants lying face down. The needles will be
217 inserted perpendicularly or obliquely, depending on the acupuncture point, to a depth of 5–30 mm, and
218 left in place for 15 min. More detailed procedures based on STRICTA are attached in S2 Table.

219 Infrared radiation (IR 3000; Haedong Medical, Ulsan, Korea) will be simultaneously applied to the
220 area where acupuncture treatment has been performed for 15 min.

221 Physical therapy will be performed using an interferential current therapy (ICT) device (Nihon Medix
222 Model 5402, Japan). The participants will be asked to lie down in the prone position with the cervical
223 area unclothed. Four self-adhesive 6 × 6 cm electrodes will be placed using a crossed pattern in the
224 lower cervical area. The intensity will be varied according to the individual tolerance. The ICT

225 stimulation will be applied for 15 min per session. The participants will be instructed to immediately
226 report any discomfort during treatment.

227 The participants in the treatment group will be instructed to apply IBA for a minimum of 6 h a day
228 over three weeks. The IBA will be positioned in the participant's mouth with the tongue tag portion
229 facing upward, and the outer centerline of the appliance will be aligned with the middle of the upper
230 teeth. The participants will be instructed to gently place their teeth on the occlusal plane without
231 clenching or applying force to their molars while wearing the device. A GMP certification (KTR-
232 AAB-16978) has been obtained for the device from the Korea Testing & Research Institute.

233 During the treatment period (Weeks 1–3), any procedure or medication aimed directly at relieving
234 painful TMD will be prohibited. However, ibuprofen will be allowed as a relief medication during the
235 study for all participants, and the dosage will be self-reported.

236 Concomitant care will be allowed for the subsequent follow-up period (week four). Any treatment
237 administered during the follow-up period will be documented during the last visit.

238

239 **Practitioner background**

240 Acupuncture treatments will be conducted by KMDs licensed by the Korean Ministry of Health and
241 Welfare, who specialize in rehabilitation medicine of Korean medicine and have at least five years of
242 clinical experience. Techniques for the entire treatment procedure will be standardized by practitioners.

243

244 **Measurements**

245 At screening, the assessment will include demographics (age and sex), anamnesis (underlying illness
246 and medical and treatment histories), physical examination (muscle palpation), and ROM of the TMJ.

247 The database will include the following information after enrollment and allocation:

248 1) Patient characteristics: height (cm), weight (kg), and vital signs (body temperature, blood pressure,
249 and pulse rate).

250 2) Outcomes: NRS for pain and bothersomeness, vertical ROM of the TMJ, GCPS, JFLS, PHQ-9,
251 EQ-5D-5L, PGIC, patient satisfaction, credibility and expectancy, and AE.

252 The primary outcome of the study will be the NRS score for pain and bothersomeness assessed at the
253 final visit at week four. Participants will select a number between 0 and 10 that best represents their
254 current pain intensity, with 0 indicating no pain and 10 denoting the most severe pain imaginable. In
255 cases where participants complain of pain in both TMJs, the side with the most severe pain will serve
256 as the reference.

257 The ROM of the TMJ is the vertical ROM measured with a ruler as the maximum range of voluntary
258 opening without pain. The test will be performed in accordance with the clinical examination protocol
259 provided by the International DC/TMD consortium [16].

260 The GCPS-1-month version uses the same item structure as the original GCPS-6-month scale, published
261 in 1992. The DC/TMD includes the GCPS-1-month version because of its recognized clinical utility in
262 assessing pain persistence. The scale has been evaluated for reliability and validity, and it consists of
263 seven items that assess pain intensity and pain-related disabilities over the past 30 days [3].

264 The JFLS is a global measure of functional limitation derived from the Research Diagnostic Criteria for
265 TMD Checklist and the Mandibular Functional Impairment Questionnaire. This scale comprises 20
266 items that assess limitations in mastication, jaw mobility, and verbal and emotional expressions.
267 Previous studies have reported its reliability and validity [17].

268 The PHQ-9 has the advantage of being aligned with the diagnostic criteria for depression in the fourth
269 edition of the Diagnostic and Statistical Manual of Mental Disorders with good sensitivity and
270 specificity. The measurement is short and practical, with only nine items. The reliability and validity of
271 the Korean version of the PHQ-9 have been validated in numerous studies [18].

272 The EQ-5D-5L, developed in 2010, is a five-level version of the EQ-5D and is a broadly used generic
273 multi-attribute health utility instrument. Composed of five items, the EQ-5D-5L is currently available
274 in >130 languages, and it demonstrated improved psychometric properties over the EQ-5D-3L version.
275 [19]

276 The PGIC and patient satisfaction questionnaires will be used to assess the subjective responses of
277 patients to symptom changes after treatment. The PGIC is a seven-point transition scale used to evaluate
278 patients' perceptions of their overall change in symptoms after intervention [20]. The patient
279 satisfaction questionnaire consists of three questions, each rated on a nine-point Likert scale.
280 Additionally, the nine-point Likert scale will be used to assess the participants' credibility and
281 expectancy toward the treatment.

282

283 **Data collection and management**

284 Electronic case report forms will be developed and validated to collect all study-related information.
285 The designated site staff will document participant data in a local participant file. The investigators will
286 manage and conduct quality control of the data according to their standard operating procedures. The
287 participant files will serve as source data for the study, and the data will be entered into the eCRF. The
288 eCRF platform will be provided by the National Clearinghouse for Korean Medicine (NCKM). To
289 ensure the integrity of the study data, only one individual will be allowed to assess the eCRF at a time,
290 and both the eCRF and supporting documents will be subjected to cross-checking. Monitoring will be
291 scheduled three times during the study: initial monitoring upon the selection of the initial patient,
292 interim monitoring at any point during the study duration, and final monitoring after the study.
293 Monitoring will be conducted by personnel independent of the study process. All documents related to
294 the study will be kept in a designated secured storage inside the study management department. All
295 records will be retained for three years after the end of the clinical study. After the retention period, the
296 records will be terminated to ensure confidentiality.

297

298 **Statistical methods**

299 Sociodemographic characteristics, treatment credibility, and expectations will be assessed for each
300 group. Primary analysis will involve an intention-to-treat approach, while per-protocol analysis will be
301 conducted simultaneously if necessary. To compare the differences between the two groups, Student's
302 t-test will be used for continuous variables, and the chi-square test or Fisher's exact test will be
303 performed for categorical variables. The efficacy variables will be the difference in the change in
304 continuous outcomes between the two groups from baseline to each evaluation time point. A repeated-
305 measures analysis of variance (RM-ANOVA) or a mixed model for repeated data will be performed to
306 test for differences in trend changes across visits. Additionally, an analysis of covariance (ANCOVA)
307 will be performed using the baseline values of each variable and covariate factors that are statistically
308 different between the groups at baseline, with the group as a fixed factor. The analysis will examine the
309 proportion of patients whose pain NRS scores decrease by half or more from baseline at each evaluation
310 time point. A Kaplan–Meier survival analysis will assess the duration from randomization to achieving
311 a reduction in NRS pain scores by less than half, and the resulting curves will be compared using the
312 log-rank test. A Cox model will be employed to compare the rate of TMJ pain reduction to less than
313 half by calculating the hazard ratio. Any missing data from participants who drop out will be handled
314 mainly by multiple imputations, and the last observation carried forward will be used for the sensitivity
315 analysis.

316 The significance level for all the analyses will be set at 0.05. All the statistical analyses will be
317 performed using the SAS version 9.4 statistical package (SAS Institute, Cary, NC, USA).

318 Subgroup analyses will be conducted, if necessary. No interim analyses will be planned for the study
319 as the sample size calculation will be tailored for the treatment period, which will make it improbable
320 to achieve a statistically significant difference between the groups before the primary endpoint.

321

322 **Confidentiality**

323 Investigators with direct access to the source data will take all necessary precautions to ensure the
324 confidentiality of the information, and participant confidentiality will be strictly maintained as far as
325 possible under the law and hospital policy. Each participant that will be enrolled in the study will be
326 encrypted by assigning a unique identification number to protect the confidentiality of personal
327 information. The medical information of participants obtained in the study will be confidential and may
328 be disclosed to third parties, as permitted by the patient's signed consent form. Additionally, medical
329 information may be provided for treatment purposes to the appropriate healthcare personnel responsible
330 for patient welfare. To the extent necessary, data from the study may be presented upon request by
331 monitoring personnel or by the Institutional Review Board (IRB) of the clinical research organization.

332

333 **Adverse event reporting and harms**

334 In a clinical study, an AE is denoted as an undesirable and unintended sign, symptom, or disease that
335 occurs after a procedure and is not necessarily causally related to the procedure. Serious AE (SAE) are
336 as follows:

- 337 1) Causes death or is life-threatening.
- 338 2) Requires hospitalization or extended hospitalization.
- 339 3) Causes persistent or significant disability or reduced functioning.
- 340 4) Other medically significant circumstances.

341 Phenomena expected to be AE will be fully recorded in detail (signs, symptoms, onset date, duration,
342 etc.), and evaluation of the AE will be recorded in a separate case report form by the investigator. The
343 causal relationship with the intervention will be evaluated according to the World Health Organization-

344 Uppsala Monitoring Centre causality categories [21]. The degree of symptoms will be evaluated using
345 the three-level classification method of Spilker [22].

346

347 **Protocol amendments**

348 If changes to the study protocol are required, all changes will be approved by the IRB of the clinical
349 research organization before implementation, except for those necessary to eliminate immediate
350 participant risk and administrative changes.

351

352 **Trial status and dissemination plans**

353 Currently, the study protocol, eCRF, and relevant documents are being reviewed before trial initiation.
354 The protocol is version 2.3 (2023-08-04). The estimated date of recruitment completion is December
355 2024.

356 The results of this study will be actively disseminated through manuscript publications and conference
357 presentations. Regardless of whether the study is completed or prematurely terminated, the clinical
358 study report will be provided to the IRB of the clinical research organization.

359

360 **Discussion**

361 In 1934, Dr. James Costen published a paper describing a syndrome characterized by ear pain, tinnitus,
362 vertigo, and limited jaw movement, which he attributed to abnormalities in the TMJ. Despite differences
363 in modern terminology, this syndrome is considered one of the earliest descriptions of what we now
364 recognize as TMD [23]. Almost a century has passed, yet the prevalence of TMD has remained fairly
365 consistent or has even increased over the years with no definitive treatment, posing a significant burden
366 both individually and globally [24].

367 Despite the promising efficacy reported by several systematic reviews of various conservative
368 treatments for TMD, such as acupuncture, occlusal splinting, photomodulation, laser, biofeedback,
369 cognitive behavioral training, hypnosis, botulinum toxin A, exercise, and medication, many studies
370 have reported conflicting results with insufficient evidence [25]. However, recent guidelines for the
371 management of TMD recommend acupuncture and splint therapy because conservative approaches
372 should be pursued first [26]. Clinically, acupuncture is used in various forms including traditional
373 acupuncture, dry needling, electroacupuncture, warm-needle acupuncture, and laser acupuncture.
374 Regardless of the study type, recent systematic reviews have revealed that acupuncture, whether used
375 independently or as an adjunct to other treatments, can significantly improve the effect rate and pain
376 intensity in patients with TMD compared with inactive controls, although the quality of the evidence
377 was low [7, 27]. A systemic review comparing conservative therapeutic modalities for TMD concluded
378 that occlusal splints, alone or in combination with other interventions, had a positive effect on short-
379 term TMD pain reduction [25]. However, owing to the inherent heterogeneity of splint studies, such as
380 the various types of splints used, delivery methods, and study designs, it is challenging to draw firm
381 conclusions [28]. Few studies have assessed the efficacy of combining acupuncture with splint therapy
382 for the treatment of TMD. One study with a design similar to ours compared acupuncture versus
383 acupuncture plus splint therapy for painful TMD over four weeks [29]. Although the combination of
384 interventions did not show significant differences between the groups, the splint group demonstrated an
385 accelerated decrease in pain and improved short-term efficacy.

386 The potential limitations of the study are as follows: 1) the intervention period was short, with no long-
387 term follow-up evaluation scheduled, which means that only short-term effects can be determined; 2)
388 since there is no standardized splint therapy for the treatment of painful TMD, the results of this study
389 will be confined to a specific splint, the IBA, and cannot be extrapolated to other types of splints.
390 Nevertheless, this randomized, assessor-blind, controlled trial will provide high-quality data on the
391 efficacy of combined treatment with acupuncture and the IBA for TMD with myalgia and may help to
392 guide future directions for the treatment of TMD with myalgia.

393

394 **Abbreviations**

| | | |
|-----|----------|---|
| 395 | AE | Adverse event |
| 396 | ANCOVA | Analysis of covariance |
| 397 | CONSORT | Consolidated standards of reporting trials |
| 398 | CRiS | Clinical Research information Service |
| 399 | DC/TMD | Diagnostic criteria for temporomandibular disorders |
| 400 | eCRF | Electronic case report form |
| 401 | EQ-5D-5L | 5-Level EuroQol-5 dimension |
| 402 | GCPS | Graded chronic pain scale |
| 403 | IBA | Intraoral balance appliance |
| 404 | IRB | Institutional review board |
| 405 | JFLS | Jaw functional limitation scale |
| 406 | KMD | Korean medicine doctor |
| 407 | NCKM | National Clearinghouse for Korean Medicine |
| 408 | NRS | Numeric rating scale |
| 409 | PHQ-9 | Patient health questionnaire-9 |
| 410 | PGIC | Patient global impression of change |
| 411 | SAE | Severe adverse event |
| 412 | STRICTA | Standards for reporting interventions in clinical trials of acupuncture |
| 413 | TMD | Temporomandibular joint disorder |
| 414 | TMJ | Temporomandibular joint |
| 415 | RM-ANOVA | Repeated measure analysis of variance |

416 ROM Range of motion

417

418 **Author's contributions**

419 All the authors have read and approved the final manuscript. Conceptualization: WCS, SYK, and JHC; methodology: WCS,
420 SYK, and JHC; writing-original draft preparation: WCS and JHC; writing-review and editing: WCS, WC, JP, HK, WSC,
421 MYS, and JHC; visualization and project administration: JHC.

422

423 **Funding**

424 This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry
425 Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: RS-2022-
426 KH127610).

427

428 **Availability of data and materials**

429 No datasets were generated or analyzed during the current study. All relevant data from this study will be made available upon
430 study completion.

431

432 **Competing interest**

433 The authors declare no competing interests.

434

435 **Reference**

436 1. Gao W, Lu J, Gao X, Zhou J, Dai H, Sun M, et al. Biomechanical effects of joint disc perforation on the
437 temporomandibular joint: a 3D finite element study. *BMC Oral Health*. 2023;23(1):943.

438 2. Scrivani SJ, Keith DA, Kaban LB. Temporomandibular disorders. *N Engl J Med*. 2008;359(25):2693-705.

439 3. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic Criteria for

- 440 Temporomandibular Disorders (DC/TMD) for Clinical and Research Applications: recommendations of the
441 International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Groupdagger. *J Oral Facial*
442 *Pain Headache*. 2014;28(1):6-27.
- 443 4. Gauer RL, Semidey MJ. Diagnosis and treatment of temporomandibular disorders. *Am Fam Physician*.
444 2015;91(6):378-86.
- 445 5. Slade GD, Ohrbach R, Greenspan JD, Fillingim RB, Bair E, Sanders AE, et al. Painful Temporomandibular
446 Disorder: Decade of Discovery from OPPERA Studies. *J Dent Res*. 2016;95(10):1084-92.
- 447 6. Kelly RB, Willis J. Acupuncture for Pain. *Am Fam Physician*. 2019;100(2):89-96.
- 448 7. Di Francesco F, Minervini G, Siurkel Y, Cicciu M, Lanza A. Efficacy of acupuncture and laser acupuncture in
449 temporomandibular disorders: a systematic review and meta-analysis of randomized controlled trials. *BMC Oral*
450 *Health*. 2024;24(1):174.
- 451 8. Fernandes AC, Duarte Moura DM, Da Silva LGD, De Almeida EO, Barbosa GAS. Acupuncture in
452 Temporomandibular Disorder Myofascial Pain Treatment: A Systematic Review. *J Oral Facial Pain Headache*.
453 2017;31(3):225-32.
- 454 9. Gupta AK, Gupta R, Gill S. Effectiveness of Vitamin D along with Splint therapy in the Vit D deficient patients
455 with Temporomandibular disorder-A Randomized, double-blind, placebo-controlled clinical trial. *J Indian*
456 *Prosthodont Soc*. 2022;22(1):65-73.
- 457 10. Al-Moraissi EA, Farea R, Qasem KA, Al-Wadeai MS, Al-Sabahi ME, Al-Iryani GM. Effectiveness of occlusal
458 splint therapy in the management of temporomandibular disorders: network meta-analysis of randomized
459 controlled trials. *Int J Oral Maxillofac Surg*. 2020;49(8):1042-1056.
- 460 11. Al-Moraissi EA, Conti PCR, Alyahya A, Alkebsi K, Elsharkawy A, Christidis N. The hierarchy of different
461 treatments for myogenous temporomandibular disorders: a systematic review and network meta-analysis of
462 randomized clinical trials [published correction appears in *Oral Maxillofac Surg*. 2021 Nov 5;:]. *Oral Maxillofac*
463 *Surg*. 2022;26(4):519-533.
- 464 12. Costa YM, Conti PC, de Faria FA, Bonjardim LR. Temporomandibular disorders and painful comorbidities:

- 465 clinical association and underlying mechanisms. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2017;123(3):288-
466 297.
- 467 13. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
468 protocols of clinical trials. *BMJ.* 2013;346:e7586. Published 2013 Jan 8. doi:10.1136/bmj.e7586
- 469 14. MacPherson H, Altman DG, Hammerschlag R, et al. Revised STAndards for Reporting Interventions
470 in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. *PLoS Med.*
471 2010;7(6):e1000261. Published 2010 Jun 8. doi:10.1371/journal.pmed.1000261
- 472 15. Wright E, Anderson G, Schulte J. A randomized clinical trial of intraoral soft splints and palliative treatment
473 for masticatory muscle pain. *J Orofac Pain.* 1995;9(2):192-199.
- 474 16. Ohrbach R, Gonzalez Y, List T, Michelotti A, Schiffman E. Diagnostic Criteria for Temporomandibular
475 Disorders (DC/TMD) Clinical Examination Protocol: Version 02June2013. www.rdc-tminternational.org
476 Accessed on March 6, 2024.
- 477 17. Pattanaik S, John MT, Chung S, Keller S. Differential Item Functioning of the Jaw Functional Limitation
478 Scale. *J Oral Facial Pain Headache.* 2023;37(1):33-46.
- 479 18. Park KY. Reliability, Validity and Clinical Usefulness of the Korean Version of the Patient Health
480 Questionnaire-9 (PHQ-9). *Global Health Nurs.* 2017;7(2):71-78.
- 481 19. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-5L: a systematic
482 review of the literature. *Qual Life Res.* 2021;30(3):647-673.
- 483 20. Domingues L, Pimentel-Santos FM, Cruz EB, et al. Is a combined programme of manual therapy and exercise
484 more effective than usual care in patients with non-specific chronic neck pain? A randomized controlled trial. *Clin*
485 *Rehabil.* 2019;33(12):1908-1918.
- 486 21. antikul C, Dhana N, Jongjarearnprasert K, Visitsunthorn N, Vichyanond P, Jirapongsananuruk O. The utility
487 of the World Health Organization-The Uppsala Monitoring Centre (WHO-UMC) system for the assessment of
488 adverse drug reactions in hospitalized children. *Asian Pac J Allergy Immunol.* 2008;26(2-3):77-82.

- 489 22. Spilker, B. Interpretation of Adverse Reactions. In Guide to Clinical Trials; Raven Press, Ltd.: New York,
490 NY, USA, 1991; pp. 565–587.
- 491 23. Michael LA. Jaws revisited: Costen's syndrome. *Ann Otol Rhinol Laryngol.* 1997;106(10 Pt 1):820-822.
- 492 24. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health
493 Care Services; Board on Health Sciences Policy; Committee on Temporomandibular Disorders (TMDs): From
494 Research Discoveries to Clinical Treatment; Yost O, Liverman CT, English R, et al., editors. Temporomandibular
495 Disorders: Priorities for Research and Care. Washington (DC): National Academies Press (US); 2020 Mar 12.
496 Appendix C, Prevalence, Impact, and Costs of Treatment for Temporomandibular Disorders. Available from:
497 <https://www.ncbi.nlm.nih.gov/books/NBK557996/>
- 498 25. Tournavitis, A., Sandris, E., Theocharidou, A., Slini, T., Kokoti, M., Koidis, P., & Tortopidis, D. (2023).
499 Effectiveness of conservative therapeutic modalities for temporomandibular disorders-related pain: a systematic
500 review. *Acta odontologica Scandinavica*, 81(4), 286–297.
- 501 26. Busse, J. W., Casassus, R., Carrasco-Labra, A., Durham, J., Mock, D., Zakrzewska, J. M., Palmer, C., Samer,
502 C. F., Coen, M., Guevremont, B., Hoppe, T., Guyatt, G. H., Crandon, H. N., Yao, L., Sadeghirad, B., Vandvik, P.
503 O., Siemieniuk, R. A. C., Lytvyn, L., Hunskar, B. S., & Agoritsas, T. (2023). Management of chronic pain
504 associated with temporomandibular disorders: a clinical practice guideline. *BMJ (Clinical research ed.)*, 383,
505 e076227.
- 506 27. Park EY, Cho JH, Lee SH, Kim KW, Ha IH, Lee YJ. Is acupuncture an effective treatment for
507 temporomandibular disorder?: A systematic review and meta-analysis of randomized controlled trials. *Medicine*
508 (Baltimore). 2023;102(38):e34950.
- 509 28. Friction J. (2006). Current evidence providing clarity in management of temporomandibular disorders:
510 summary of a systematic review of randomized clinical trials for intra-oral appliances and occlusal therapies. *The*
511 *journal of evidence-based dental practice*, 6(1), 48–52.
- 512 29. Sant'Anna CBM, Caxias FP, Zuim PRJ, Januzzi MS, Silva EVFD, Turcio KHL. Treatment of Masticatory
513 Muscle Pain with Acupuncture: Is It Necessary to Associate with Occlusal Splints?. *J Acupunct Meridian Stud.*
514 2021;14(3):89-94.

